Biomarker failures

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 202-204

  Ioannidis, John P A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; GENETIC VARIABILITY; GENOTYPE; HUMAN; NET RECLASSIFICATION INDEX; NOTE; PROTEOMICS; VALIDATION PROCESS;

HUMANS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872040796     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.185801     Document Type: Note

References (17)

1. Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
2. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. JAMA 2012;307:37-8.
3. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. (Pubitemid 34178440)
4. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97:315-9. (Pubitemid 40310281)
5. Bell AW, Deutsch EW, Au CE, Kearney RE, Beavis R, Sechi S, et al., and HUPO Test Sample Working Group. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods 2009;6:423-30.
6. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010;2:46ps42.
7. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 2012;42:1027-36.
8. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57.
9. Marchionni L, Wilson RF, Wolff AC, Marinopoulos S, Parmigiani G, Bass EB, Goodman SN. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008;148:358-69. (Pubitemid 351665467)
10. Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008;82:593-9. (Pubitemid 351726114)
11. Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. Eur J Clin Invest 2010;40:64-8.
12. Mihaescu R, van Zitteren M, van Hoek M, Sijbrands EJ, Uitterlinden AG, Witteman JC, et al. Improvement of risk prediction by genomic profiling: reclassification measures versus the area under the receiver operating characteristic curve. Am J Epidemiol 2010;172:353-61.
13. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010;42:570-5.
14. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med 2012;4:133ra58.
15. WordPress.com. Retraction watch: archive for the 'anil potti retractions' category. http://retractionwatch.wordpress.com/category/by-author/anil- pottiretractions/(Accessed June 2012).
16. Baggerly KA, Coombes KR. What information should be required to support clinical "omics" publications? Clin Chem 2011;57:688-90.
17. Ioannidis JP, Khoury MJ. Improving validation practices in "omics" research. Science 2011;334:1230-2.